About Geovax Labs (OTCMKTS:GOVX)
GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company's platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company's development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company's clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.
Industry, Sector and Symbol
Trailing P/E Ratio-1
Forward P/E Ratio-1.25
Sales & Book Value
Price / Sales5.05
Price / CashN/A
Book Value($0.02) per share
Price / Book-2.50
Return on EquityN/A
Return on Assets-433.47%
Geovax Labs (OTCMKTS:GOVX) Frequently Asked Questions
What is Geovax Labs' stock symbol?
Geovax Labs trades on the OTCMKTS under the ticker symbol "GOVX."
How were Geovax Labs' earnings last quarter?
Geovax Labs Inc (OTCMKTS:GOVX) issued its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.01). The biotechnology company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.30 million. View Geovax Labs' Earnings History.
When will Geovax Labs make its next earnings announcement?
Who are some of Geovax Labs' key competitors?
Some companies that are related to Geovax Labs include Sunshine Heart (CHFS), ESSA Pharma (EPIX), Strata Skin Sciences (SSKN), Secure Point Technologies (IMSC), Mateon Therapeutics (MATN), Lombard Medical (EVARF), Dextera Surgical (DXTR), TearLab (TEAR), Delcath Systems (DCTHD), Affymax (AFFY), BG Medicine (BGMD), Tetralogic Pharmaceuticals (TLOG), Imris (IMRSQ), Echo Therapeutics (ECTE) and Sino Biopharmaceut (SBMFF).
Who are Geovax Labs' key executives?
Geovax Labs' management team includes the folowing people:
- David A. Dodd, Independent Chairman of the Board (Age 65)
- Robert T. McNally Ph.D., President, Chief Executive Officer, Director (Age 67)
- Mark W. Reynolds CPA, Chief Financial Officer, Corporate Secretary (Age 53)
- Harriet Latham Robinson Ph.D., Chief Scientific Officer, Director (Age 77)
- Randal D. Chase Ph.D., Director (Age 66)
- Dean G. Kollintzas, Independent Director (Age 41)
- John N. Spencer Jr., CPA, Independent Director (Age 76)
Who owns Geovax Labs stock?
Geovax Labs' stock is owned by many different of retail and institutional investors. Top institutional shareholders include
SABBY MANAGEMENT, LLC
SABBY MANAGEMENT, LLC
(5.50%). View Institutional Ownership Trends for Geovax Labs.
How do I buy Geovax Labs stock?
Shares of Geovax Labs can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geovax Labs' stock price today?
One share of Geovax Labs stock can currently be purchased for approximately $0.05.
How big of a company is Geovax Labs?
Geovax Labs has a market capitalization of $4.18 million and generates $830,000.00 in revenue each year. The biotechnology company earns $-3,270,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Geovax Labs employs 11 workers across the globe.
How can I contact Geovax Labs?
Geovax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The biotechnology company can be reached via phone at 678-384-7220 or via email at [email protected]
MarketBeat Community Rating for Geovax Labs (GOVX)MarketBeat's community ratings are surveys of what our community members think about Geovax Labs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Geovax Labs (OTCMKTS:GOVX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Geovax Labs (OTCMKTS:GOVX) Earnings History and Estimates Chart
Geovax Labs (OTCMKTS GOVX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/23/2018|| || || || || || || || |
|11/9/2017||Q3 2017||($0.01)||($0.01)||$0.30 million||$0.25 million||View||N/A|
Geovax Labs (OTCMKTS:GOVX) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.04 EPS
Next Year EPS Consensus Estimate: $-0.07 EPS
Dividend History for Geovax Labs (OTCMKTS:GOVX)
No dividend announcements for this company have been tracked by MarketBeat.com
Geovax Labs (OTCMKTS GOVX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.40%
Geovax Labs (OTCMKTS GOVX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/5/2015||Randal D Chase||Director||Buy||10,000||$0.19||$1,900.00|| |
|4/23/2015||Mark Reynolds||CFO||Buy||30,000||$0.17||$5,100.00|| |
|4/20/2015||Randal D Chase||Director||Buy||30,000||$0.17||$5,100.00|| |
Geovax Labs (OTCMKTS GOVX) News Headlines
Geovax Labs (OTCMKTS:GOVX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Geovax Labs (OTCMKTS:GOVX) Income Statement, Balance Sheet and Cash Flow Statement
Geovax Labs (OTCMKTS GOVX) Stock Chart for Monday, January, 22, 2018